Core Insights - The National Healthcare Security Administration (NHSA) has officially announced the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which includes 114 new drugs and 19 drugs in the first version of the Commercial Health Insurance Innovative Drug Catalog, effective from January 1, 2026 [1][2][3] Industry Summary - The NHSA has adjusted the drug catalog for the eighth time since its establishment, with a total of 949 new drugs added over the years, and the medical insurance fund has spent over 4.6 trillion RMB on negotiated drugs, driving sales exceeding 6 trillion RMB [1][2] - The new catalog includes 50 first-class innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [3] - The inclusion of drugs for major diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as rare diseases and chronic conditions, addresses gaps in basic medical insurance coverage [2][3] Company-Specific Updates - Green Leaf Pharmaceutical has successfully included five new products in the NHSA's drug catalog, including MiMeiXin® and ZhanBiJia® [4] - Fuhong Hanlin announced that its product Fuzhuoning® has been included in the NHSA's drug catalog for specific indications [5] - Junshi Biosciences reported that its products Tuoyi® and Junshida® have been successfully included in the NHSA's drug catalog [6] - Innovent Biologics has successfully added seven innovative products to the new NHSA drug catalog, including Daboru® and Xindimian® [6]

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Core Insights - Green Leaf Pharmaceutical (02186) announced that five new products have been successfully included in the National Medical Insurance Drug List (2025) and the Commercial Health Insurance Innovative Drug List (2025) [1] Group 1: New Product Inclusion - The five new products include: - Mimesin (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Drug List [1] - Zanbija (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug List [1] - Baituowei (Injectable Goserelin Microspheres) and Ruiketuo (Injectable Risperidone Microspheres (II)) have successfully renewed their contracts and continue to be included in the National Medical Insurance Drug List [1]

集团相信，医保与商保的协同联动，是国家保基本、促创新，大力支持创新药高质量发展的重要举措。 集团五款新产品通过多元准入路径纳入多层次医疗保障体系，不仅有助于提升相关疾病领域患者的用药 可及性，切实减轻其治疗负担，也将进一步加快这些产品的市场渗透与覆盖，为其长期的高质量增长打 下坚实基础。 格隆汇12月7日丨绿叶制药(02186.HK)公告，集团共有五款新产品成功纳入由国家医疗保障局发布的 《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(国家医保药品目录)或《商业健康保险 创新药品目录(2025年)》(商保创新药目录)。 该五款新产品包括：米美欣(羟考酮纳洛酮缓释片)、瑞百莱(棕榈酸帕利哌酮注射液(Ⅱ))首次纳入国家医 保药品目录；赞必佳(注射用芦比替定)成功入选商保创新药目录；百拓维(注射用戈舍瑞林微球)、瑞可 妥(注射用利培酮微球(Ⅱ))顺利续约，继续被纳入国家医保药品目录。 ...

Core Viewpoint - Green Leaf Pharmaceutical (02186) has successfully included five new products in the National Medical Insurance Drug List (2025) and the Commercial Health Insurance Innovative Drug List (2025) [1] Group 1: New Product Inclusion - The five new products include: - Mimesin® (Oxycodone Naloxone Extended-Release Tablets) and Ruibailai® (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Drug List [1] - Zanbija® (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug List [1] - Baituowei® (Injectable Goserelin Microspheres) and Ruiketuo® (Injectable Risperidone Microspheres (II)) have successfully renewed their inclusion in the National Medical Insurance Drug List [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 自願性公告 本集團五款新產品成功納入 2025年國家醫保藥品目錄或商保創新藥目錄 瑞百萊® （棕 櫚 酸 帕 利 哌 酮 注 射 液（Ⅱ））是全球首個且唯一實現「首 月 僅 需1針」給 藥 方 案 的 帕 利 哌 酮 長 效 針 劑，在 中 國 獲 批 的 適 應 症 為 用 於 精 神 分 裂 症 急 性 期 和 維 持 期 的 治 療。該 產 品 同 時 也 已 在 美 國 獲 批 上 市。相 較 於 傳 統 的 帕 利 哌 酮 長 效針劑首月需要注射2次的給藥方案（第1天和第8天各注射1次），瑞 百 萊®僅 需 單 次351mg起 始 劑 量 即 可 完 成 初 始 治 療，簡 化 用 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 绿叶制药集团有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02186 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.02 | USD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.02 | USD | | 200,000,000 | ...

Core Insights - The pharmaceutical industry is witnessing a shift in Alzheimer's disease (AD) drug development, with Chinese companies increasingly entering the field while multinational corporations face setbacks [1][2][3] Group 1: Current Developments in Alzheimer's Drug Research - Novo Nordisk announced that its two large Phase III trials for Semaglutide in treating Alzheimer's disease did not meet primary endpoints [1] - Chinese pharmaceutical companies, such as Green Leaf Pharmaceutical and Kangfang Biotech, are advancing their own AD drug candidates, with Green Leaf's LY03017 recently receiving FDA approval for clinical trials [1][2] - The number of drugs under development for AD in China ranks second globally, following the United States, indicating a growing interest and investment in this area [2] Group 2: Challenges Faced by Multinational Corporations - Major multinational companies like Pfizer, Roche, and Johnson & Johnson have faced failures in AD drug development due to unclear disease mechanisms and ineffective clinical trial results [2][3] - Notably, Biogen's Aducanumab is set to exit the AD treatment landscape due to conflicting Phase III trial results, while other drugs like Lecanemab and Donanemab have received limited approval [3] Group 3: Factors Driving Chinese Companies' Confidence - Chinese companies are motivated by advancements in diagnostic technologies and a significant unmet clinical need in the AD space [4] - The integration of biomarker testing and advanced imaging techniques has improved diagnostic accuracy, addressing previous challenges in the field [4] - Green Leaf Pharmaceutical is exploring multiple indications for its LY03017 drug, indicating a strategic approach to capitalize on the unmet needs in AD and related disorders [4]

Core Insights - The pharmaceutical industry is witnessing a shift in Alzheimer's disease (AD) drug development, with Chinese companies increasingly entering the field while multinational corporations face setbacks [1][2][3] Group 1: Current Developments in AD Drug Research - Novo Nordisk announced that its two large Phase III trials for Semaglutide in treating Alzheimer's did not meet primary endpoints, indicating challenges in the AD drug development landscape [1] - Chinese pharmaceutical companies, such as Green Leaf Pharmaceutical and Kangfang Biotech, are advancing their own AD drug candidates, with Green Leaf's LY03017 recently receiving FDA approval for clinical trials [1][2] - The number of drugs under development for AD in China ranks second globally, following the United States, highlighting the growing interest and investment in this area [2] Group 2: Challenges Faced by Multinational Corporations - Major multinational companies like Pfizer, Roche, and Johnson & Johnson have faced failures in AD drug development due to unclear disease mechanisms and ineffective clinical trial results [2][3] - Notably, Biogen's Aducanumab is set to exit the AD treatment space due to contradictory Phase III trial results, while other drugs like Lecanemab and Donanemab have received mixed responses from regulatory bodies [3] Group 3: Factors Driving Chinese Companies' Confidence - Chinese companies are motivated by advancements in diagnostic technologies and a significant unmet clinical need in the AD space, particularly for psychiatric symptoms associated with the disease [4] - The combination of improved diagnostic methods and a large patient population with unmet needs is driving the confidence of Chinese firms in pursuing AD drug development [4] - Green Leaf Pharmaceutical is exploring multiple indications for its LY03017, indicating a strategic approach to address various aspects of AD and related disorders [4]

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) has seen its stock price increase by over 3%, currently trading at 3.2 HKD with a trading volume of 28.3181 million HKD [1] Group 1 - The stock price of Green Leaf Pharmaceutical rose by 3.22% [1] - The current trading price is 3.2 HKD [1] - The trading volume reached 28.3181 million HKD [1]